Calavo Growers, Inc. Announces Third Quarter and Nine-Month Period Ended July 31, 2025 Financial Results
1. Third quarter sales fell slightly to $178.8 million compared to last year. 2. Fresh segment sales decreased by 5%, while prepared segment sales surged 40%. 3. FDA detention hold costs were $4.2 million, impacting fresh segment profits significantly. 4. Net income totaled $4.7 million, down from $5.4 million in the prior year. 5. Company expects continued growth, projecting prepared segment sales will reach $115 million.